Use of rilpivirine in HIV-1-infected individuals in routine clinical practice from 2012 to 2017 in France

Abstract Objectives We assessed virological outcomes of rilpivirine use in France from 2012 to 2017, in three groups of people living with HIV (PLHIV): (i) antiretroviral (ARV)-naive PLHIV; (ii) ARV-experienced PLHIV switching to rilpivirine while failing therapy; and (iii) ARV-experienced PLHIV swi...

Full description

Saved in:
Bibliographic Details
Published in:Journal of antimicrobial chemotherapy 2021-02, Vol.76 (2), p.467-476
Main Authors: Potard, Valérie, Gallien, Sébastien, Canestri, Ana, Costagliola, Dominique, Abel, S, Abgrall, S, Allavena, C, Bazus, H, Becker, A, François, Benezit, Bouvet de la Maisonneuve, P, Bregigeon, S, Brugnon, A, Caby, F, Calin, R, Cheret, A, Costagliola, D, Truchis, P De, Denis, B, Duvivier, C, Enel, P, Fischer, H, Ghosn, J, Goussef, M, Grabar, S, Huber, F, Jacomet, C, Joly, V, Katlama, C, Khuong, M, Makinson, A, Marchand, L, Martin-Blondel, G, Matheron, S, Meynard, J, Miailhes, P, Nacher, M, Piet, E, Piroth, L, Ploquin, M, Rabier, V, Robineau, O, Rouveix Nordon, E, Tattevin, P
Format: Article
Language:English
Subjects:
Life Sciences
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Objectives We assessed virological outcomes of rilpivirine use in France from 2012 to 2017, in three groups of people living with HIV (PLHIV): (i) antiretroviral (ARV)-naive PLHIV; (ii) ARV-experienced PLHIV switching to rilpivirine while failing therapy; and (iii) ARV-experienced PLHIV switching to rilpivirine while virologically controlled. Methods Virological success (VS) was defined as a plasma HIV-1 viral load (VL) 50 copies/mL or one VL >50 copies/mL followed by a treatment switch prior to the next VL measurement. The cumulative incidence of VS was assessed considering rilpivirine discontinuation, loss to follow-up and death as competing risks, while estimates of cumulative incidence of VF accounted for loss to follow-up and death. Results Among the 2166 ARV-naive PLHIV initiating rilpivirine, the 4 year cumulative incidence of VS was 91.0% and was associated with baseline VL. Among the 2125 ARV-experienced PLHIV switching to rilpivirine while failing therapy, the 4 year cumulative incidence of VS was 82.5% and was associated with lower VL, higher CD4 and less than three prior ARVs. Among the 11 828 ARV-experienced PLHIV switching to rilpivirine while virologically controlled, the 4 year cumulative incidence of VF was 9.6%. The risk of VF was lower among MSM, for PLHIV with CD4 ≥ 500 cell/mm3, without a prior AIDS event, or with a longer VL suppression at baseline. Conclusions Rilpivirine-containing regimens yielded high rates of viral suppression in most participants, while it was ineffective when used outside the marketing authorization in naive participants.
ISSN:0305-7453
1460-2091
DOI:10.1093/jac/dkaa449